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The crosstalk between inflammation and tumorigen-
esis is now clearly established. However, how inflam-
mation is elicited in the metastatic environment and
the corresponding contribution of innate immunity
pathways in suppressing tumor growth at secondary
sites are poorly understood. Here, we show that
mice deficient in Nlrp3 inflammasome components
had exacerbated liver colorectal cancer metastatic
growth, which was mediated by impaired inteleu-
kin-18 (IL-18) signaling. Control of tumor growth
was independent of differential cancer cell coloniza-
tion or proliferation, intestinal microbiota effects, or
tumoricidal activity by the adaptive immune system.
Instead, the inflammasome-IL-18 pathway impacted
maturation of hepatic NK cells, surface expression
of the death ligand FasL, and capacity to kill FasL-
sensitive tumors. Our results define a regulatory
signaling circuit within the innate immune system
linking inflammasome activation to effective NK-
cell-mediated tumor attack required to suppress
colorectal cancer growth in the liver.
INTRODUCTION
Colorectal cancer (CRC) is the third most commonly diagnosed
cancer globally, accounting for an annual 1.36 million cancer
cases and 694,000 deaths in the US (Ferlay et al., 2015). The
prognosis of CRC patients is good for early-stage cancer, but
the majority of cases are diagnosed at later stages. It is esti-
mated that approximately 40% of CRC patients progress to fatal
metastasis (Tsikitis et al., 2014), 80% being confined to the liver
while the remaining 20% are associated with other visceral
organs (Manfredi et al., 2006).
Inflammation and immunity are important determinants of
tumorigenesis, impacting cancer development from initiation,promotion, and progression to cancer equilibrium and suppres-
sion, respectively (Balkwill and Coussens, 2004; Schreiber et al.,
2011). Although cell-autonomous aberrations are considered the
initiators of cancer, the interaction of cancer cells with their
microenvironment, particularly with immune cells therein, results
in stimulatory or inhibitory effects that govern tumor escape
versus elimination. Although much effort has been invested in
deciphering the function of the adaptive immune system in tumor
immunosurveillance (Galon et al., 2013; Schreiber et al., 2011),
the contribution of specific innate immunity pathways to this
process is less understood. Among the effectors of the innate
immune system are germline-encoded pattern recognition
receptors (PRRs) that, upon sensing microbial- or danger-asso-
ciated molecular patterns, elicit an inflammatory response to
restore homeostasis. A number of PRRs, including members of
the Nod-like receptor (NLR) and HIN200 families, operate by
assembling large molecular complexes referred to as inflamma-
somes (Latz et al., 2013). These signaling scaffolds trigger innate
immunity by activating the protease caspase-1, which cleaves
immune and metabolic substrates (Keller et al., 2008; LeBlanc
et al., 2014; Shao et al., 2007), most notably the pro-inflamma-
tory cytokines interleukin-1b (IL-1b) and IL-18, inducing inflam-
mation and an inflammatory form of cell death termed pyroptosis
(Labbe´ and Saleh, 2008).
We and others have previously implicated the inflammasome
pathway in suppression of colitis and colitis-associated colo-
rectal cancer. Mice deficient in inflammasome components,
including Nlrp3, Nlrp6, Asc, caspase-1 and caspase-11, Il-18
or Il-18r, exhibit increased colitis and tumorigenesis compared
to wild-type (WT) mice in the azoxymethane-dextran sulfate so-
dium (AOM-DSS) model (Allen et al., 2010; Dupaul-Chicoine
et al., 2010; Elinav et al., 2011; Huber et al., 2012; Salcedo
et al., 2010; Zaki et al., 2010a, 2010b). The tumor-suppressive
effect of the inflammasome in this context was not at the level
of immunosurveillance but mediated by the function of IL-18 in
maintaining epithelial barrier integrity and triggering tissue repair
after ulceration.
IL-1b and IL-18 exert pleiotropic effects in inflammation and
tumorigenesis. Indeed, both pro- and anti-tumorigenic functions
have been previously reported for these cytokines. For instance,Immunity 43, 751–763, October 20, 2015 ª2015 Elsevier Inc. 751
IL-1b is spontaneously produced by advanced melanomas,
conferring growth advantage and invasion (Okamoto et al.,
2010; Qin et al., 2011). Transgenic expression of human IL1B
in the stomach of mice also promotes tumorigenesis through
autocrine effects on NF-kB activation and recruitment of
myeloid-derived suppressor cells (MDSCs) (Tu et al., 2008). In
contrast, IL-1b is necessary for anti-cancer immunosurveillance
after chemotherapy (Eisenbarth and Flavell, 2009; Ghiringhelli
et al., 2009). Similarly to IL-1b, IL-18 performs dual functions in
tumorigenesis. Besides its indirect tumor-suppressive role in
colitis-associated CRC, IL-18 has been classically associated
with a T helper 1 skewed immunostimulatory anti-tumorigenic
response through its ability to induce IFN-g (Okamura et al.,
1995) and its effects on enhancing the cytolytic activity of
T cells and NK cells (Novick et al., 2013). In contrast to these
anti-tumorigenic functions, IL-18 enhances, rather than sup-
presses, hepatic melanoma metastasis. Carrascal et al. (2003)
demonstrated that IL-18 signaling stimulated microvascular
arrest of tumor cells throughmodulation of endothelial cell adhe-
sion. Furthermore, a more recent study reported an inhibitory
effect of IL-18 on NK cell tumoricidal function through induction
of the immunosuppressive co-stimulatory molecule PD-1 on
their surface (Terme et al., 2011).
The seemingly contradictory function of inflammasome-
dependent cytokines in tumor promotion and anti-tumor immu-
nity is proposed to be context dependent and tissue specific.
Because the tumors in most spontaneous and experimental
CRCanimalmodels do not progress tometastases, andbecause
the primary site of CRC metastasis is the liver, an immunologi-
cally unique organwith a relatively tolerogenicmicroenvironment
(Jenne and Kubes, 2013), we chose to use an intrasplenic model
of CRCmetastasis to the liver to genetically dissect the impact of
the inflammasome pathway on the immune surveillance mecha-
nisms of syngenic metastatic lesions in vivo. We demonstrate a
critical role for the Nlrp3 inflammasome in suppressing CRC
growth in the liver. IL-18, but not IL-1 signaling, was required
for inflammasome-mediated immunosurveillance. Both the pro-
duction and the response to this cytokine relied solely on the
innate immune system. IL-18 controlledmetastatic growth, inde-
pendently of T and B cells, by promoting hepatic NK cell matura-
tion andpriming Fas-mediated cytotoxicity. The anti-tumorigenic
function of the inflammasome required Fas-sensitive tumors
and could be recapitulated in an independent model of lung
metastasis. This study defines a regulatory circuitry in the innate
immune system that links inflammasome activation by endoge-
nous danger signals to efficient activation of NK cell tumoricidal
function leading to tumor elimination at metastatic sites.
RESULTS
Caspase-1-Deficient Mice Are Highly Susceptible to
Colorectal Cancer Liver Metastatic Growth
To investigate the role of the inflammasome in liver CRC
metastasis, we implemented a model of intrasplenic injection
of transplantable tumor cells derived from a murine primary co-
lon carcinoma (MC38) (Rosenberg et al., 1986) that lead to liver
metastasis in a C57BL/6 syngenic immunocompetent host.
Because caspase-1 is the central effector of all canonical inflam-
masomes defined to date, we first evaluated the metastatic752 Immunity 43, 751–763, October 20, 2015 ª2015 Elsevier Inc.burden of caspase-1-deficient mice (also carrying an inactivating
mutation in Casp-11; herein referred to as Ice/ mice)
compared to that of C57BL/6 WT mice on days 14 and 21
post-injection (p.i.) (Figure 1A). Until day 14 p.i., the weight of
the liver did not vary from that of untreated mice and was similar
between WT and Ice/ mice (Figures 1B, 1D, and S1A). Quan-
tification of MC38 foci coverage (herein denoted as ‘‘metastatic
foci’’) on hematoxylin and eosin (H&E)-stained liver tissue sec-
tions revealed a similar area covered by metastatic lesions on
day 14 p.i. between the two mouse genotypes (Figures 1B and
1E). In contrast, we observed that Ice/mice had heavier livers
compared toWT animals starting on day 18 p.i. (Figure S1A), and
this difference was more marked on day 21 p.i. (Figures 1C and
1F). Histological analysis revealed that changes in liver weight
correlated with larger hepatic MC38 foci coverage in Ice/
mice compared to WT animals (Figures 1C and 1G). To address
the basis of this differential tumor growth, we first determined
whether ablation of inflammasome signaling might have resulted
in a pre-damaged liver at baseline. Quantification of the two liver
enzymes AST and ALT in the circulation revealed no differences
in liver damage between WT and Ice/mice (Figure S1B). Next,
we evaluated whether cancer cell proliferation or cell death were
affected by loss of inflammasome signaling. We assessed cell
proliferation potential in metastatic foci on days 14 and 21 p.i.
by immunofluorescence staining of liver tissue sections with an-
tibodies against proliferating cellular nuclear antigen (PCNA).
Histological examination (Figure 1H) andquantification (Figure 1I)
of PCNA+ cells revealed no differences in proliferation between
WT and Ice/ mice. In contrast, TUNEL staining that marks
dying cells revealed reduced cell death levels in metastatic
foci in Ice/ mice compared to WT mice at equivalent tumor
burden on day 14 p.i. (Figures 1J and 1K). Co-staining of liver
sections with TUNEL and antibodies against cytokeratin 20
that labels intestinal epithelial cells (IECs) indicated that cell
death occurred primarily in the MC38 colorectal cancer cells
(Figure 1L). Together, these results suggest that activation of
the inflammatory caspase pathway suppresses MC38 growth
in the liver by triggering cell death of colon carcinoma cells within
metastatic foci.
Nlrp3, but Not Nlrc4 or Aim2, Is Required for
Suppression of CRC Metastatic Growth in the Liver
Caspase-1 is synthesized as a zymogen, which requires activa-
tion by proximity within an inflammasome for biological activity.
Seven inflammasomes havebeendefined todate, each respond-
ing to distinct sets of stimuli. NLRP3 recognizes a wide array of
cellular stress signals, including ionic disturbances, metabolites,
mitochondrial stress, high extracellular ATP concentrations, par-
ticulate matters, and microbial products (Latz et al., 2013). In
contrast, NLRC4 and AIM2 are restricted to sensing bacterial fla-
gellum components and cytosolic DNA, respectively (Latz et al.,
2013). Because the liver is continuously exposed to diverse mi-
crobial products through the portal vein circulation, and because
danger-associated molecular patterns (DAMPs) are likely to be
released in the metastatic environment, we examined the role
of different inflammasome-forming NLR proteins and AIM2 in
the control of CRC metastatic growth. In contrast to Ice/
mice, both Nlrc4/ mice and Aim2/ mice had an unadulter-
ated tumor control mechanism, exhibiting no differences in either
Figure 1. Ice–/– Mice Exhibit Enhanced
MC38 Colorectal Cancer Growth in the Liver
(A) Schematic representation of CRC metastatic
growth in the liver model induced by intrasplenic
injection of the C57BL/6 colon carcinoma MC38
cells. Mice were injected on day 0 and sacrificed
on either day 14 or 21 post-injection.
(B and C) Representative pictures of the liver and
hematoxylin and eosin (H&E) staining of liver sec-
tions fromWT and Ice/mice sacrificed on day 14
(B) or 21 (C) after MC38 intrasplenic injection.
(D–G) WT or Ice/mice liver weight (D and F) and
CRC foci coverage (E and G) on day 14 (D and E) or
21 (F and G) after MC38 injection (n R 4 per time
point per genotype).
(H–K) Epifluorescence images of MC38 foci in liver
sections from WT or Ice/ mice on day 14 or 21
post-MC38 injection stained with antibodies
against PCNA to mark dividing cells (H) or TUNEL
to mark dying cells (J) and Hoechst to label nuclei.
Insets correspond to boxed regions. n = 3mice per
genotype. Scale bars represent 200 mm. Quantifi-
cation of stain-positive cells in (H) and (J) shown in
(I) and (K), respectively.
(L) Immunofluorescence images of MC38 foci in
liver sections stained with TUNEL and antibodies
against cytokeratin 20 (CK20) that mark intestinal
epithelial cells and bile duct (BD) cells but not
hepatocytes (H) (scale bars represent 200 mm);
inset 1, zoom 2.53; inset 2, zoom 23. Asterisks
label CK20-negative cells that are also TUNEL
negative.
Graphs represent the mean ± SEM. Statistical
analysis was performed with Student’s t test;
*p < 0.05, **p < 0.001, ***p < 0.0001. All experi-
ments were repeated two to three times. See also
Figure S1.liver weight or metastatic coverage compared to WT animals on
day 21 p.i. (Figures 2A–2D). Nlrp3/ mice phenocopied Ice/
mice, showing higher tumor burden in the liver, as measured by
liver weight (Figure 2E) and foci coverage (Figure 2F). Nlrp3
inflammasome activation is tightly regulated and requires two
signals for activation: a priming signal (or signal 1) that generally
converges on NF-kB activation and is needed to induce Nlrp3
expression, andanactivating signal (or signal 2) required for com-
plex assembly (Latz et al., 2013). To determinewhether theMC38
adenocarcinoma cells released factors that primed or activated
Nlrp3, we examined the effect of MC38 conditioned media
(CM) on the inflammasome response by using bone-marrow-
derived macrophages (BMDMs). MC38-derived CM, but not
control CM from BMDMs, robustly primed the inflammasome
response, inducing caspase-1 activation and secretion of IL-1b
and IL-18 when combined with a signal 2 (e.g., ATP) (FiguresImmunity 43, 751–7632G, 2H, and S2A). To decipher inflam-
masome-activating signals in the tumor
microenvironment in vivo, we first as-
sessed the contribution of the microbiota.
We administered an antibiotic cocktail in
the drinking water of WT mice from the
time of weaning until sacrifice for a total
duration of 9weeks (Figure 2I). Quantifica-tion of bacterial 16S rRNA in the mouse fecal pellets by qPCR
showed amarked depletion of themicrobiota between untreated
and treated mice (4-log difference) (Figure S2B). However, this
microbiota deregulation did not impact tumor growth, as shown
by the fact that liver weight was equivalent in the two groups (Fig-
ure 2J). Next, we pharmacologically assessed the contribution of
three potential DAMPs, namely reactive oxygen species (ROS),
uric acid, and extracellular ATP (Latz et al., 2013). We treated
MC38-bearing WT mice with N-acetylcysteine (NAC) to quench
ROS, allopurinol to block the production of uric acid, or suramin
to inhibit P2 receptors, including extracellular ATP signaling (Fig-
ure 2I). AlthoughNACor allopurinol administration did not impact
liverweight orMC38 foci coverage (Figures 2K and2L), treatment
with suramin resulted in increased tumor burden in the liver (Fig-
ures 2M and 2N). Nlrp3 activation downstream of extracellular
ATP signaling has previously been demonstrated in the context, October 20, 2015 ª2015 Elsevier Inc. 753
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Figure 2. The NLRP3 Inflammasome Is Required for Suppression of MC38 Growth in the Liver Independently of P2x7r
(A–F)Nlrc4/mice (A, B), Aim2/mice (C, D), orNlrp3/mice (E, F) liver weight (A, C, E) andmetastatic foci coverage (B, D, F) compared toWTmice on day 21
after intrasplenic injection of MC38 cells (nR 4 mice per genotype per experiment).
(G) ELISA quantification of IL-1b levels in BMDMs from either WT (n = 5) or Ice/ (n = 3) mice. BMDMs were left untreated (UT) or treated with MC38 conditioned
media (CM), ATP, or CM+ATP.
(H) Immunoblot analysis of caspase-1 and IL-18 levels in the supernatant of BMDMs from (G).
(I) Schematic representation of the antibiotic, allopurinol (Ap), NAC, or suramin (Sn) treatment regimens. At weaning (week 3), WT mice were administered an
antibiotic cocktail (Abx) in their drinking water for 9 weeks. WTmice were injected with allopurinol (10 mg/g) i.p. from day 10 to day 20. 1%NACwas added to the
drinking water ofWTmice throughout the experiment. WTmice were injected i.p. with either PBS or suramin (1mg) in 100 ml PBS starting on day 0, three times per
week until the end of the experiment.
(J) Liver weight of control (Ctrl, regular water) or Abx-treated WT mice 21 days after intrasplenic MC38 injection (n = 10 mice per treatment).
(K and L) Liver weight (K) and CRC foci coverage (L) of control (Ctrl), allopurinol (Ap), or NAC-treated WT mice 21 days after intrasplenic injection (n = 6–7 per
treatment).
(M and N) PBS- or suramin-treated WT mice liver weight (M) and CRC foci coverage (N) on day 21 after intrasplenic MC38 injection (n = 6–8 mice per treatment).
(O and P) WT or P2xr7/mice liver weight (O) and metastatic foci coverage (P) on day 21 after intrasplenic injection of MC38 cells (n = 5–6 mice per genotype).
Graphs represent the mean ± SEM. Statistical analysis was performed by Student’s t test; *p < 0.05, ***p < 0.0001. All experiments were repeated two to three
times, except for the experiment in (J) that was done once. See also Figure S2.of Nlrp3 inflammasome-mediated anti-tumor immunity after
chemotherapy (Ghiringhelli et al., 2009). To explore the specific
contribution of ATP signaling to the control of CRC hepatic
growth, we examined the response of P2rx7/ mice, which are754 Immunity 43, 751–763, October 20, 2015 ª2015 Elsevier Inc.deficient in the purinergic receptor P2x7r, a ligand-gated ion
channel that activates Nlrp3 after ATP binding (Ferrari et al.,
2006; Martinon et al., 2009). Surprisingly, P2rx7was dispensable
for tumor control (Figures 2O and 2P), suggesting either that
Figure 3. The Inflammasome Tumor-Suppressive Function Is Mediated by IL-18 Production by Radio-Sensitive and Radio-Resistant Cells
(A–F) Il1r1/mice (A, B), Il18/mice (C, D), or Il18r1/mice (E, F) liver weight (A, C, E) and CRC foci coverage (B, D, E) compared to WT mice on day 21 after
intrasplenic injection of MC38 cells (nR 6 mice per genotype per experiment).
(G) Schematic representation of the murine recombinant IL-18 (rIL-18) dosing schedule. Ice/ mice were injected with MC38 cells on day 0. From day 10 until
day 20, i.p. injections of 0.25 mg murine rIL-18 in 50 ml PBS were performed.
(H and I) PBS- or rIL-18-treated Ice/ mice liver weight (H) and CRC foci coverage (I) on day 21 after intrasplenic MC38 injection (n = 5 mice per treatment).
(J) Bone marrow chimeric mice CRC foci coverage on day 21 after intrasplenic MC38 injection (n = 4–8 per group).
(K) Epifluorescence images of MC38 foci fromWT or Il18/mice on day 21 post-injection using antibodies to mark macrophages (F4/80, green), IL-18 (red), and
Hoechst (blue) staining for the nuclei. Insets correspond to boxed regions; scale bar represents 200 mm.
(L) Photomicrographs of immunohistochemical staining of mouse liver tissue sections from chimeric mice of the indicated genotype showing IL-18 (Permanent
Red) and F4/80 (Emerald Green) expression. Cells expressing both proteins are in dark blue. Insets (zoom 2.53) correspond to boxed regions; scale bar
represents 100 mm.
Graphs represent themean ± SEM. Statistical analysis was performed via Student’s t test; *p < 0.05, **p < 0.001, ***p < 0.0001. All experiments were repeated two
to three times, except for the experiment in (J) that was done once.broad-spectrum inhibition of ATP receptors was required for
tumor suppression or that suramin exerted its effects through
an alternate pathway. Collectively, these results indicate that
the Nlrp3 inflammasome is primed by tumor cells and is required
to suppress CRC metastatic growth in the liver.
IL-18 Is Required for an Effective Inflammasome-
Mediated Suppression of CRC Growth in the Liver
To identify the target(s) of caspase-1 responsible for controlling
CRC metastatic growth in the liver, we first examined the contri-
bution of its two canonical substrates, IL-1b and IL-18, by
exploring the phenotype of Il1r1/, Il18/, and Il18r/ mice.
In contrast to Il1r1/ mice (insensitive to both IL-1a and
IL-1b), which are not different from WT animals in their ability
to restrict tumor growth (Figures 3A and 3B), ablation of IL-18signaling was deleterious; it resulted in larger metastatic tumor
coverage in the livers of Il18/ and Il18r/ mice (Figures 3C–
3F). To further confirm that the susceptibility of Ice/ mice
was due to lack of IL-18 production, we performed a rescue
experiment, in which 0.25 mg of murine recombinant IL-18
(rIL-18) was administered daily from days 10 to 20 (Figure 3G).
rIL-18 reduced the CRC burden in the liver of Ice/ mice from
55% in vehicle-injected controls to 34% foci coverage (Figures
3H and 3I), which is similar to the tumor burden observed in
WTmice (Figures 3B, 3D, and 3F). Next, to determine the cellular
compartment required for the secretion of IL-18 in the liver, we
generated bone marrow chimeras and investigated their
response to MC38 intrasplenic cell injection. As expected, con-
trol Il18/mice receiving Il18/ bonemarrow (Il18/ > Il18/)
had larger metastatic foci coverage in the liver than control WTImmunity 43, 751–763, October 20, 2015 ª2015 Elsevier Inc. 755
mice transplanted withWT bonemarrow (WT >WT). On the other
hand, Il18/mice receivingWT bone marrow (WT > Il18/) and
WT recipients of IL-18-deficient bone marrow (Il18/ >WT) had
similar phenotypes (Figure 3J). This suggested that IL-18 expres-
sion in both the radiosensitive and radioresistant compartments
is required for anti-metastatic control. Immunofluorescence
staining of tissue sections from tumor-bearing mice revealed
that F4/80+ myeloid cells are the prevalent producers of IL-18
in the liver (Figure 3K), consistent with previous reports localizing
Nlrp3 inflammasome activation to Kupffer cells (Huang et al.,
2013; Kim et al., 2015). Bone marrow chimeras and orthotopic
liver transplantation studies have previously distinguished two
subsets of Kupffer cells, the first radioresistant and long-lived
originating from intra-hepatic precursors and the second
radiosensitive and rapidly replaced from hematopoeitic precur-
sors (Klein et al., 2007). Examination of liver tissue sections
from Il18/ > WT chimeric mice revealed the presence of an
IL-18+F4/80+ sub-population of cells, consistent with incomplete
depletion of IL-18-expressing macrophages by irradiation (Fig-
ure 3L). Thus, Kupffer cell heterogeneity might underlie the inter-
mediate tumor control phenotype observed in our bone marrow
chimera experiment. However, we cannot exclude that other ra-
dioresistant cells might also be involved.
Control of Hepatic Metastasis Occurs Independently of
the Adaptive Immune System
IL-18 was initially discovered because of its ability to enhance
IFN-g production by CD8+ T cells and NK cells after stimulation
with IL-12 (Novick et al., 2013). Because the requirement for the
adaptive immune system has not been previously explored in
this system, we tested the response of Rag1/ mice to intra-
splenic injection of MC38 cells. Interestingly, the metastatic
burden observed in Rag1/ mice was similar to that of WT an-
imals (Figures S3A and S3B), suggesting that T, B, and NKT cells
are not required for the suppression of MC38 liver metastatic
growth. To confirm that IL-18 exerted its effects through the
innate immune system, we next generated Rag1/Il18/
mice and assessed their tumor control response. Unlike
Rag1/ mice, Rag1/Il18/ mice exhibited increased liver
weight and a larger MC38 foci area (Figures 4A and 4B). To
explore the impact of impaired inflammasome signaling on
innate immune cell subsets in the liver, we examined by flow
cytometry the frequencies and absolute numbers of tumor-
infiltrating leukocytes (TILs) in the liver of WT or Ice/ mice.
No significant differences were found for NK cells, inflammatory
monocytes, neutrophils, resident macrophages, or dendritic
cells between WT and Ice/ mice (Figures 4C, 4D, S4A, and
S4B). Because of the critical tumoricidal role of NK cells, we
further examined their maturation in the liver. Murine NK cells ac-
quire effector functions after a 4-stage maturation process
from CD11bloCD27lo/ CD11bloCD27hi/ CD11bhiCD27hi/
CD11bhiCD27lo, with the latter being fully mature cytotoxic NK
cells (Chiossone et al., 2009). FACS staining of hepatic NK cells
on day 14 p.i. showed a decrease in the frequencies and
numbers of fully activated NK cells (CD11bhiCD27lo) in Ice/
mice compared to WT animals (Figures 4E–4G). Staining for
KLRG1 and CD69, amarker for NK cell cytotoxic activity, also re-
vealed decreased frequencies of CD69hiKLRG1lo hepatic NK
cells in Ice/ mice compared to WT animals (Figures 4H–4J).756 Immunity 43, 751–763, October 20, 2015 ª2015 Elsevier Inc.This NK cell phenotype was restricted to hepatic NK cells in tu-
mor-bearing mice at day 14 p.i., as indicated by the fact that the
maturation or activation of peripheral blood NK cells at this time
point was similar in WT and Ice/ mice (Figures S3C and S3D).
Furthermore, no differences in NK cell maturation were observed
under steady-state conditions (day 0) in the liver, blood, or
spleen (Figures S3E and S3F). Surprisingly, the ability of NK cells
to produce IFN-g after isolation from the liver and either restim-
ulation with PMA/ionomycin (Figures 4K and 4L) or plate-bound
NK1.1 (Figures 4M, 4N, and S3G) was not affected in Ice/
mice. Consistently, although increased hepatic tumor load was
observed in Ifng/ mice, administration of recombinant IL-18
to these mice exerted tumor suppression (Figures S3H and
S3I), suggesting that IL-18 operated independently of IFN-g-
mediated tumor control mechanisms. Similarly, the lytic activity
of liver NK cells from either genotype on RMA cells was similar
(Figure S3J), consistent with unimpaired function of granzymes
and perforin, which are the primary executors in this killing assay
(Wallin et al., 2003). Collectively, our results suggest that IL-18
mediates its tumor-suppressive function independently of the
adaptive immune system or IFN-g signaling. Our data also
show that impairment of inflammasome signaling impacts the
maturation of hepatic NK cells in tumor-bearing mice.
IL-18 Acts on NK Cells to Control CRC Metastasis to the
Liver
NK cells have been shown to positively correlate with patient
survival in numerous cancers (Imai et al., 2000). To determine
the contribution of NK cells to the control of MC38 hepatic
metastasis, we examined the response of Jak3W81R mice, which
lack NK cells while also lacking adaptive immune effectors
(Bongfen et al., 2012). Unlike Rag1/ mice, Jak3W81R mice
had an increased metastatic burden as early as day 19 p.i. (Fig-
ures 5A and 5B), indirectly implicating NK cells in suppressing
tumorigenesis. To confirm a role for NK cells in tumor immu-
nosurveillance in this model, we administered the NK-cell-
depleting anti-asialo GM1 (aGM1) antibody to WT mice and
determined their response to MC38 liver growth. Consistent
with the results obtained with Jak3W81R mice, depletion of NK
cells in WT animals increased their metastatic burden compared
to PBS-treated controls (Figures 5C and 5D). Moreover, the
adoptive transfer of WT splenocytes into Jak3W81Rmice reduced
their liver metastatic burden significantly compared to that of
Il18r/ splenocytes (Figure 5E), indicating that IL-18 signaling
on NK cells is needed to control MC38 liver growth. We next ad-
dressed whether IL-18 exerted additional functions on tumor
control beyond aNK-cell-mediated effect. To do so, we depleted
NK cells prior to injecting MC38 cells into Ice/ mice using
aGM1 and subsequently administered rIL-18 from day 10 to
day 19 (Figure 5F). As expected, ending the experiment on day
19 p.i. resulted in a smaller tumor burden in Ice/mice (Figures
5G and 5H) compared to their observed load on day 21 p.i.
(Figures 1F, 1G, and S1A), providing a window to observe further
increase in tumorigenesis due to NK cell depletion. Interestingly,
rIL-18 administration did not alter the metastatic phenotype of
NK-cell-depleted Ice/ mice (Figures 5G and 5H), in contrast
to what was observed in NK-cell-replete Ice/ mice (Figures
3G–3I). To further demonstrate that IL-18 signaling is required
directly on NK cells, we generated Il18r/Il15r/ > WT mixed
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Figure 4. Restriction of Colorectal Cancer
Growth in the Liver Occurs Independently
of the Adaptive Immune System and IFN-g
Production
(A and B) Rag1/ and Rag1/Il18/ mice liver
weight (A) and CRC foci coverage (B) on day 21 after
intrasplenic injection of MC38 cells (n = 6–8 mice per
genotype).
(C and D) Percentages (C) and absolute numbers (D)
of NK cells (NK1.1+ cells) in the liver of WT or Ice/
mice 14 days after intrasplenic injection of MC38
cells.
(E) Representative FACS plots of CD11b and CD27
NK1.1+ cells in liver leukocytes from WT or Ice/
mice collected on day 14 after MC38 intrasplenic
injection.
(F andG) Percentages (F) and absolute numbers (G) of
NK cells according to their maturation phenotype.
Double negative (DN), CD11bCD27; double posi-
tive (DP), CD11b+CD27+ (n = 5 per genotype).
(H) Representative FACS plots of CD69 and KLRG1
NK1.1+ cells in liver leukocytes from WT or Ice/
mice collected on day 14 after MC38 intrasplenic
injection.
(I and J) Percentages (I) and absolute numbers (J) of
NK cells according to their expression of CD69 and
KLRG1 (n = 3 per genotype).
(K–N) Representative histograms (K, M) and quantifi-
cation graph (L, N) of IFN-g production by NK cells
after overnight stimulation of liver leukocytes purified
on day 14 post-MC38 intrasplenic injection from WT
or Ice/ mice with PMA/ionomycin (P/I) (K, L) or
plate-bound NK1.1 (M, N) (n = 5 mice per genotype).
Graphs represent the mean ± SEM. Statistical
analysis was performed by Student’s t test; *p < 0.05.
All experiments were repeated two to three times. See
also Figure S3.
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Figure 5. IL-18 Mediates Natural Killer Cell Tumoricidal Activity in the Liver
(A and B) WT or Jak3W81R mice liver weight (A) and CRC foci coverage (B) on day 19 post-MC38 intrasplenic injection (n = 4–7 mice per genotype).
(C and D) PBS- or anti-asialo GM1-treated WT mice liver weight (C) and CRC foci coverage (D) on day 19 post-MC38 intrasplenic injection (n = 6–7 mice per
treatment).
(E) CRC foci coverage on day 19 in Jak3W81R mice that received PBS injection (Ctl) or splenocyte adoptive transfers 5 days post-MC38 intrasplenic injection. The
data are pooled from two experiments (n = 7–10 mice per genotype).
(F) Schematic representation of rIL-18 dosing schedule in Ctl or NK cell-depleted Ice/mice. Starting on day5, Ice/mice were administered with anti-asialo
GM1 antibodies i.p. every 5 days. On day 0, MC38 cells were intrasplenically injected, and on day 10, mice received i.p. daily injections of either PBS or rIL-18.
(G andH) Liver weight (G) andCRC foci coverage (H) of Ice/mice replete or deplete of NK cells and receiving or not rIL-18was determined on day 19 after MC38
intrasplenic injection (n = 3–5 mice per group).
Graphs represent the mean ± SEM. Statistical analysis was performed by Student’s t test; *p < 0.05, **p < 0.001, ***p < 0.0001, ns, not significant. All experiments
were repeated two to three times. See also Figure S4.bone marrow chimeras to deplete IL-18r expression specifically
on NK cells (Figures 6A–6C). As expected, loss of Il18r on
NK cells recapitulated the impairment in immunosurveillance
observed in inflammasome signaling-deficient mice or mice
lacking NK cells (Il15ra/ > WT, Figure 6C). Overall, this sug-
gests that IL-18 signaling on NK cells contributes to the control
of MC38 metastatic growth in the liver.
NK Cell Tumoricidal Function Is Mediated by IL-18
Signaling of FasL Cytotoxicity
Because we observed that the capacity of hepatic NK cells to
produce IFN-g was unaffected in Ice/ mice (Figures 4K–4N)
and that recombinant IL-18 treatment of Ifng/mice was effec-
tive at reducing tumor burden (Figure S3I), we hypothesized that
IL-18 regulatedNKcell lytic activity independently of IFN-g. Inter-
estingly, it was previously shown that suramin, which we used as
a putative P2 blocker and that significantly increasedMC38met-
astatic liver growth (Figures 2M and 2N), inhibited Fas-induced
apoptosis (Eichhorst et al., 2004). Furthermore, Smyth et al.
(2004) have previously reported an IFN-g-independent function
of IL-18 in mediating NK cell suppression of metastasis that
required tumor cell sensitivity to Fas ligand (FasL). Although758 Immunity 43, 751–763, October 20, 2015 ª2015 Elsevier Inc.ex vivo treatment of splenicNKcellswith IL-18 for 45min robustly
induced Ifng expression in WT but not Il18r/ NK cells, as pre-
dicted, it did not impact Fasl expression at this time point, as
determined by qPCR analysis (Figures 6D and 6E). In contrast,
IL-18 stimulated a rapid and robust upregulation of FasL protein
on the surface of NK cells, which occurred within 45 min of stim-
ulation, asmeasured by FACS analysis of themean fluorescence
intensity (MFI) of FasL (Figures 6F and 6G). To interrogate
whether inflammasome-mediated metastasis control was medi-
ated by FasL-induced cytotoxicity, we first determined the
sensitivity of MC38 cells to FasL killing in vitro. As shown in
Figure S5A, treatment of MC38 cells with FasL (10 ng/ml)
induced approximately 50% cell death, as quantified by propi-
dium iodide (PI) staining and FACS. In contrast, the murine
rectal carcinoma CMT93 cells were markedly resistant to
FasL-induced cell death (Figure S5A). Consistent with a role for
FasL-mediatedNK cytotoxicity in the control ofMC38metastatic
growth, Faslgld/gldIl15r/ > WT mixed bone marrow chimeras
failed to controlMC38metastatic liver growth (Figure 6C). Collec-
tively, our results demonstrate that IL-18 signaling regulates FasL
surface expression on NK cells, which contributes to their tumor-
icidal function and suppression of CRC liver growth.
A D
E
GF
B C
Figure 6. Expression of IL-18r by NK Cells and FasL Are Required for CRC Growth Restriction in the Liver
(A) Schematic representation of experimental layout. Mice were irradiated and reconstituted with bone marrow fromWT (n = 9), Il15ra/ (n = 9), Il18r1/ (n = 8),
Faslgld/gld (n = 10), or a 1:1 cell ratio of Il15ra/:Il18r1/ (n = 9) or Il15ra/:Faslgld/gld (n = 9) mice 6 weeks prior to intrasplenic injection of MC38 cells.
(B) Representative FACS plots of IL-18r-expressing NK1.1+ cells in the spleen from WT bone marrow chimeric mice collected on the day of MC38 intrasplenic
injection.
(C) CRC foci coverage in chimeric mice on day 19 after MC38 intrasplenic injection. Graphs represent the mean ± SEM. Statistical analysis was performed by
Student’s t test; *p < 0.05, **p < 0.001.
(D and E) mRNA derived from untreated NK cells or NK cells treated with IL-2, IL-12, and IL-15 or with IL-2, IL-12, IL-15, and IL-18 fromWT (n = 5) or Il18r/ (n = 3)
mice 45 min after treatment was analyzed for the expression of Ifng (D) and Fasl (E).
(F and G) Representative histogram (F) and mean fluorescence intensity (G) of FasL expression on WT (n = 5) or Il18r/ (n = 3) NK cells, before or 45 min after
treatment with IL-2, IL-12, and IL-15 or with IL-2, IL-12, IL-15, and IL-18.
See also Figure S5.To confirm that the susceptibility phenotype of Ice/ mice
was determined by the sensitivity of tumor cells to FasL, we
examined the response of WT and Ice/ mice to intrasplenic
injection of FasL-insensitive CMT93 cells. Consistent with our
hypothesis, Ice/mice had a similar hepatic metastatic burden
compared to WT mice when FasL-resistant tumor cells were
used in this liver metastasis model (Figures S5B and S5D). We
further tested the sensitivity of Lewis lung carcinoma (LLC) cells
to FasL and found that, like MC38 cells, they were highly sensi-
tive to Fas-induced killing (Figure S5A), consistent with a previ-
ous report (Smyth et al., 2004). This allowed us to interrogate
whether inflammasome-mediated anti-metastatic control was
tissue specific. After intravenous injection of LLC cells that
home to the lung, Ice/mice had a significantly higher metasta-tic burden than WT mice on day 28 p.i. (Figures S5E and S5F).
Collectively, these results suggested that the sensitivity of tumor
cells to FasL is a determinant of whether caspase-1 activation
and subsequent IL-18 release contributes to control of metasta-
tic growth in secondary organs.
DISCUSSION
Colorectal cancer-associated deaths occur due to its dissem-
ination to secondary organs, primarily the liver (Manfredi et al.,
2006; Tsikitis et al., 2014). Through investigation of the function
of the inflammasome pathway in an experimental animal model
of CRC metastatic liver growth, we have genetically delineated
a circuitry in the innate immune system linking sensing of dangerImmunity 43, 751–763, October 20, 2015 ª2015 Elsevier Inc. 759
signals by the Nlrp3 inflammasome to activation of hepatic NK
cell cytolytic activity required for metastatic control. Inflamma-
some-mediated tumor suppression required IL-18 signaling on
NK cells but was independent of IFN-g production. Instead,
IL-18 promoted NK cell maturation and primed their tumoricidal
function, which required FasL-sensitive tumor cells.
The liver is constantly exposed to intestinal microbial products
through the portal vein circulation, but its unique tolerogenic
environment prevents unwanted immune responses. Engage-
ment of the inflammatory caspase pathway after CRC liver colo-
nization indicated inflammasome activation by a danger signal
emanating in response to metastatic lesion formation. In this
model, we have ruled out the contribution of cytosolic DNA
sensing by Aim2 or recognition of flagellated bacteria by Nlrc4,
because ablation of either’s gene was dispensable for metasta-
tic control.
The Nlrp3 inflammasome is activated by a wide spectrum
of agonists including both microbial and sterile triggers (Latz
et al., 2013). The microbiota has surfaced in recent years as
an important determinant of health and disease. Notably, it
was recently demonstrated that antibiotic-treated or germ-
free mice respond poorly to cancer immunotherapy and
chemotherapy. The commensal microbiota was required for
promoting cytotoxicity after chemotherapy by modulating the
tumor microenvironment (Iida et al., 2013; Viaud et al., 2013).
Although significant depletion of bacterial content with the
use of antibiotics was achieved in our experiments, it did not
modulate the anti-metastatic response, suggesting that Nlrp3
activation was not impaired by deregulation of the microbial
ecology. However, we cannot exclude that Nlrp3 activation
might be mediated by a microbial ligand derived from the re-
maining intestinal microbiota. The production of ROS has
been linked to cancer promotion and in some cases to the acti-
vation of the Nlrp3 inflammasome (Fang et al., 2009). Similarly,
uric acid is a principal endogenous DAMP released from injured
cells (Shi et al., 2003) and along with ROS was considered
herein as a potential DAMP upstream of Nlrp3 activation in
the tumor microenvironment. However, treatment with NAC or
allopurinol, a uric acid analog that reduces uric acid production,
did not affect the formation of metastatic foci. Although a num-
ber of Nlrp3 agonists, including microbial triggers, were previ-
ously reported to require extracellular ATP and P2X7 receptor
signaling for inflammasome activation (Latz et al., 2013), abla-
tion of P2xr7 did not inhibit the inflammasome in our model,
as shown by the fact that P2xr7/ mice did not phenocopy
Nlrp3/ or Ice/ animals and were equivalent to WT animals
in their metastatic burden. Surprisingly, suramin, which has
been commonly used as a putative P2 receptor blocker in
studies interrogating Nlrp3 inflammasome activation by ATP
(Coddou et al., 2011), had a striking effect on tumor evasion.
Interestingly, suramin was previously investigated for its anti-
tumorigenic properties in adrenocortical and prostate cancer
and was reported to inhibit death receptor-induced apoptosis
by modulating activation of caspase-8 within the death-
inducing signaling complex (DISC) (Eichhorst et al., 2004).
Although we could not identify the agonist that activated the
Nlrp3 inflammasome, we demonstrated that colorectal cancer
cells primed the inflammasome. This is in accordance with a
previous report demonstrating that tumor cells promoted760 Immunity 43, 751–763, October 20, 2015 ª2015 Elsevier Inc.inflammation and tumorigenesis through the secretion of fac-
tors that engaged the NF-kB pathway (Kim et al., 2009).
The anti-tumorigenic activity of IL-18 has been classically
linked to its IFN-g-inducing capacity both in cytotoxic T cells
and NK cells (Novick et al., 2013). Control of liver metastatic
growth occurred independently of T, B, and NKT cells but
required NK cells. Interestingly, although NK cells from inflam-
masome-deficient mice were impaired in controlling MC38 liver
cell growth, their IFN-g production was intact and their ability
to kill RMA cells was similar to that of WT mice. Of note, RMA
cells are insensitive to Fas-induced cytotoxicity but killed by
NK cells through perforin- and granzyme-mediated cytotoxicity
(Wallin et al., 2003). Interestingly, our results showed that the
anti-metastatic function of inflammasome signaling required
FasL-sensitive tumor cells. Notably, Ice/mice were equivalent
to WT animals in their ability to control metastatic growth of
FasL-resistant tumor cells, suggesting that IL-18 production
has otherwise a minimal impact on immunosurveillance in this
model. Mechanistically, IL-18 controls a rapid FasL expression
on the surface of NK cells, potentially through relocation of intra-
cellular FasL stores, as previously described in cytotoxic T lym-
phocytes (He et al., 2010). Notably, the site of IL-18 production,
and likely its local concentration, greatly affects metastasis
outcome. For instance, in contrast to host-derived IL-18, which
we show in this model to be anti-metastatic, IL-18 production
by cancer cells was shown to promote melanoma liver metas-
tasis in an animal model (Valca´rcel et al., 2014), and an IL-18-
dependent gene expression signature was shown to correlate
with invasive human melanoma (Crende et al., 2013). Addition-
ally, in a model of lung metastasis, IL-18 production by cancer
cells was reported to induce the development of an immature
population of NK cells, which promoted metastasis (Terme
et al., 2011, 2012). This highlights the heterogeneity of cancer
cell responses to IL-18 and the ability of this immunoregula-
tory cytokine to positively or negatively affect the outcome of
metastasis.
FasL plays a crucial role in cellular homeostasis and immune
surveillance by inducing cell death through its receptor Fas. As
such, the therapeutic potential of FasL has been explored to
target tumor cells. However, this approach has had limitations,
because of hepatotoxicity. Interestingly, tumor cells usurp
the FasL-Fas pathway to their advantage. For instance, some
colon cancer cells upregulate FasL on their surface to facilitate
seeding in the liver by promoting epithelial-mesenchymal transi-
tion (Zheng et al., 2013) and inducing hepatocyte cell death (Li
et al., 2009). In addition, to evade immunosurveillance mediated
by FasL killing, these tumor cells also express decoy receptors
and c-FLIP. This not only ensures cancer cell survival and resis-
tance to Fas-induced cell death, but also promotes Fas-driven
cell proliferation (Li et al., 2009).
Harnessing the immune system to fight cancer and metastatic
growth is the next breakthrough in cancer therapy. However, this
can be achieved only by in-depth characterization of cancer cells
in relation to their microenvironment. Here, we have provided a
model view of how the inflammasome, IL-18, and FasL can be
utilized against certain types of metastatic cancer to enhance
immune surveillance. To gain a more complete picture of the
significance of this mechanism in metastasis control, it will be
important to determine the impact of inflammasome component
expression and activation in conjunction with the status of death
receptor pathway effectors on cancer progression and patient
outcome.
EXPERIMENTAL PROCEDURES
Mice
Animals used throughout the study were sex-matched 6- to 12-week-old
mice on a C57BL6/J background and bred as separate colonies. C57BL6/J,
Rag1/, Il1r1/, Il18/, Il18r1/,P2xr7/, andFaslgld/gldmicewereobtained
from The Jackson Laboratory. Ice/ mice were obtained from R. Flavell (Yale
University) (Kuida et al., 1995). Nlrp3/, Nlrc4/, and Aim2/ mice were
fromGenentech.Jak3W81Rmiceweregenerated throughanENUscreen, aspre-
viously reported (Bongfen et al., 2012). All of the abovemouse strains were bred
in house and experiments were performed according to the guidelines of the
Animal Ethics committee of McGill University (Canada). Il15ra/ mice were
maintained at the University of Connecticut Health Center (Lodolce et al., 1998).
Animal Models
To induce the development of liver metastasis, mice were injected intraspleni-
callywith23105MC38or 1.53106CMT93cells in 50ml of phosphate-buffered
saline (PBS), followedbysplenectomy3minafter injections. PBS-injectedmice
served as controls. Mice were sacrificed 14 or 21 days after the initial injection.
For the induction of lung metastasis, 2 3 105 LLC cells (ATCC) in 100 ml PBS
were injected intravenously (i.v.) and mice were sacrificed 21 days later. To
quantify the metastatic burden, H&E slides were scanned with ScanScope
XT (Aperio Technologies). To calculate the metastatic burden with the Image-
Scope software, the area occupied by metastatic foci was divided by the total
surfacearea. For adoptive transfer, 203106splenocytes fromdonormicewere
injected i.v. on day 5. Where indicated, 0.25 mg of mouse recombinant IL-18
(MBL, B002-5) was injected intraperitoneally (i.p.) daily between days 10 and
20or 1mgsuramin (Sigma, S2671)was injected i.p. three timesperweek, start-
ing on the day of the intrasplenic injection. 1% (weight/volume) NAC (Sigma,
A7250) was added to the drinking water of the animals. 10 g/kg of allopurinol
(Sigma, A8003) was given i.p. daily starting on day 10.
Generation of Bone Marrow Chimeras
3 days prior to irradiation, 1 mg/ml sulfamethoxazole (Sigma, S7507) and
0.2 mg/ml trimethoprim (Sigma, T7883) were given in the drinking water.
Mice were kept on this regimen for an additional 3 weeks. Recipient mice
were lethally irradiated in the afternoon with 1,000 rads using the X-Ray
RS-2000 Biological irradiator. The next morning, red-blood-cell-depleted
bone marrow from sex-matched donor mice was injected i.v. (ratio of one
donor for three recipients). For the mixed bone marrow experiment, a 1:1
Il15r/:Il18r/ or Faslgld/gld ratio was used. The extent of engraftment was
verified after 6 weeks by FACS staining of blood lymphocytes.
Depletion of NK Cells
50 ml anti-asialo GM1 (Wako Chemicals, Cat #986-10001)/mouse was injected
i.p. every 5 days starting 5 days prior to the intrasplenic injection. Confirmation
of NK cell depletion in the spleen was performed after splenectomy on day
0 and in the liver at endpoint.
NK Isolation
For the lytic assay, target RMA cells were labeled with the cell proliferation dye
eFluor 670 (eBioscience cat# 65-0840). Liver NK cells were isolated with NK
cell isolation II (Miltenyi biotech cat#130-096-892) with autoMACS and incu-
bated with target cells at a ratio of 20:1 for 4 hr at 37C. Cells were then stained
with 7-AAD (eBioscience, 00-6993-50) to quantify cell death. For the ex vivo
restimulation, splenic NK cells were isolated as above and stimulated with
20 ng/ml IL-2 (Preprotech, 212-12), 10 ng/ml IL-12 (Preprotech, 210-12),
50 ng/ml of IL-15 (210-15), and 50 ng/ml of IL-18 (MBL, B002-5) in complete
media for 45 min prior to RNA isolation or FACS analysis.
Quantitative Real-Time PCR
Total RNA (2 mg) was reverse transcribed with M-MLV reverse transcriptase
(InVitrogen, Cat# 28025-013) and random hexamers in a volume of 20 mlaccording to the manufacturer’s protocol. The primers used for quantitative
real-time PCR are available upon request. All reactions were normalized to
the housekeeping gene L32 to quantify the relative gene expression and
were then analyzed by the 2DDCT method.
Statistical Analysis
Data are represented as mean ± standard error of the mean (SEM). Two-tailed
Student’s t test was used for evaluating statistical significance between
groups. *p < 0.05; **p < 0.001; ***p < 0.0001; n.s., not significant. All experi-
ments were repeated twice or more unless otherwise specified in the figure
legends.
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